In vitro activity of biapenem and other carbapenems against Russian clinical isolates of Pseudomonas aeruginosa, Acinetobacter spp., and Enterobacterales

Objective. To evaluate in vitro activity of biapenem and other clinically available carbapenems against Russian clinical isolates of Enterobacterales, Pseudomonas aeruginosa и Acinetobacter spp., including isolates with acquired fermentative mechanisms of resistance to β-lactams. Materials and Methods. A total of 3139 Enterobacterales isolates, 793 P. aeruginosa isolates and 634 Acinetobacter spp. isolates from hospitalized patients in 63 hospitals from 35 Russian cities were included in the study during 2018-2019. Minimal inhibitory concentrations (MIC) for biapenem and other antimicrobials were determined in accordance with ISO 20776-1:2006.

Susceptibility of clinical Enterobacterales and Pseudomonas aeruginosa isolates to ceftazidimeavibactam in Russia: multicenter local laboratory databased surveillance

Objective. To assess the in vitro activity of ceftazidime-avibactam against clinical Enterobacterales and Pseudomonas aeruginosa isolates in various regions of Russia based on results of local susceptibility testing by disk diffusion method. Materials and Methods. Overall, 160 laboratories located in 61 Russian cities participated in this surveillance during 2018-2020. All consecutive clinical isolates of Enterobacterales and Pseudomonas aeruginosa in each participating laboratory were included in the study. Ceftazidime-avibactam susceptibility testing was done by disc-diffusion method in accordance with current EUCAST recommendations.

Application of AMRmap: «from the general to the specific» approach by the example of Klebsiella pneumoniae

The options for the use of «Plot By» tab in the web platform AMRmap are reviewed in the article. Description of some functionality is supported by the specific examples, and Klebsiella pneumoniae was selected as a study object. The analysis elements …

Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015–2016”

Objective. To assess rates of antimicrobial resistance and production of the clinically important acquired resistance mechanisms (extended spectrum beta-lactamases [ESBL] and carbapenemases) in nosocomial strains of Enterobacterales, and to determine genotypes and prevalence of “international high-risk clones” among carbapenemase-producing Klebsiella pneumoniae isolated in various Russian regions within the “MARATHON 2015–2016“ study. Materials and Methods. A total of 2786 non-duplicate nosocomial isolates of Enterobacterales, including 1316 isolates of K. pneumoniae and 837 isolates of Escherichia coli isolated in 49 hospitals from 25 cities in Russia in 2015–2016 were studied.

Molecular characterization of extended-spectrum beta-lactamase-producing Enterobacterales isolates collected from blood culture in patients with hematological malignancies

Objective. The objective of the study was to evaluate the prevalance of genes blaTEM, blaSHV and blaCTX-M among extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales isolates collected from blood culture in patients with hematological malignancies. Materials and methods. The prospective multicenter study included Enterobacterales isolates collected from blood culture in hematological patients from 10 Russian hospitals (2003-2015). The isolates were screened for ESBLs by the phenotypic methods (CLSI 2017). Genes encoding TEM, SHV and CTX-M were detected using polymerase chain reaction (PCR) by specific primers.

Antimicrobal resistance of nosocomial carbapenemase-producing Enterobacterales in Russia: results of surveillance, 2014-2016

Objective. To assess the prevalence and antimicrobial susceptibility of carbapenemase-producing Enterobacterales (CPE). Materials and Methods. A total of 5539 Enterobacterales isolates recovered from hospitalized patients in 52 medical institutions in 27 cities in Russia in 2014-2016 were tested. Antibiotic susceptibility testing (AST) was performed using broth microdilution method according to ISO 20776-1:2006. Avibactam was tested in combinations with beta-lactams at fixed concentration of 4 mg/l. AST results were interpreted according to EUCAST v8.

Ceftolozane/tazobactam – the «new player» in a battle against multiresistant pathogens

Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials. In this paper …